These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9821241)

  • 21. Rheumatic diseases and Klinefelter's syndrome.
    Rovenský J
    Isr Med Assoc J; 2006 Feb; 8(2):119-21. PubMed ID: 16544736
    [No Abstract]   [Full Text] [Related]  

  • 22. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Rheumatic diseases as risk factors for cardiovascular disease].
    Nurmohamed MT; Voskuyl AE; van der Horst-Bruinsma IE; Dijkmans BA
    Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1921-4. PubMed ID: 16999275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Rheumatism and Arteriosclerosis].
    SCHETTLER G
    Arztl Wochensch; 1955 Jul; 10(26-27):604-5. PubMed ID: 14398532
    [No Abstract]   [Full Text] [Related]  

  • 25. Risk assessment of skin in rheumatic disease.
    Firth J
    Nurs Times; 2005 Jun 14-20; 101(24):54-5, 57-8. PubMed ID: 15977479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pregnancy and rheumatic diseases.
    Gayed M; Gordon C
    Rheumatology (Oxford); 2007 Nov; 46(11):1634-40. PubMed ID: 17623748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythrocyte adhesiveness/aggregation: a novel biomarker for the detection of low-grade internal inflammation in individuals with atherothrombotic risk factors and proven vascular disease.
    Berliner S; Rogowski O; Aharonov S; Mardi T; Tolshinsky T; Rozenblat M; Justo D; Deutsch V; Serov J; Shapira I; Zeltzer D
    Am Heart J; 2005 Feb; 149(2):260-7. PubMed ID: 15846263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins in atherothrombosis.
    Colli S; Werba JP; Tremoli E
    Semin Vasc Med; 2004 Nov; 4(4):407-15. PubMed ID: 15861322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should we be morbid about comorbidities in the rheumatic diseases?
    Elewaut D; Goodson N; Fleischmann R
    Rheumatology (Oxford); 2013 Jan; 52(1):1-2. PubMed ID: 23238977
    [No Abstract]   [Full Text] [Related]  

  • 30. The cardiovascular manifestations of rheumatic diseases.
    Goodson NJ; Solomon DH
    Curr Opin Rheumatol; 2006 Mar; 18(2):135-40. PubMed ID: 16462518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant hypertension caused by ascendent aortoiliac thrombosis.
    PALOU J
    Angiology; 1960 Dec; 11():518-21. PubMed ID: 13732343
    [No Abstract]   [Full Text] [Related]  

  • 32. Chronic occlusive disease of the terminal aorta and its surgical treatment: report of case.
    GIBERSON RG; WAUGH JM; HINES EA; FAULCONER A
    Proc Staff Meet Mayo Clin; 1954 Mar; 29(5):137-43. PubMed ID: 13145636
    [No Abstract]   [Full Text] [Related]  

  • 33. Actions to identify and reduce the risk of atherothrombosis in susceptible patients.
    Foxton J
    Prof Nurse; 2004 Jul; 19(11):30-3. PubMed ID: 15317336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombosis in the pathogenesis of atherosclerosis.
    Chandler AB
    J Med Assoc Ga; 1967 Aug; 56(8):319-23. PubMed ID: 6042094
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis.
    Goto S; Bhatt DL; Röther J; Alberts M; Hill MD; Ikeda Y; Uchiyama S; D'Agostino R; Ohman EM; Liau CS; Hirsch AT; Mas JL; Wilson PW; Corbalán R; Aichner F; Steg PG;
    Am Heart J; 2008 Nov; 156(5):855-63, 863.e2. PubMed ID: 19061698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors and pathogenesis of atherosclerosis.
    Beaumont JL
    Triangle; 1975; 14(1):9-16. PubMed ID: 1162729
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases.
    Asten P; Barrett J; Symmons D
    J Rheumatol; 1999 Aug; 26(8):1705-14. PubMed ID: 10451066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isoprostane formation and inhibition in atherothrombosis.
    Patrono C; Falco A; Davì G
    Curr Opin Pharmacol; 2005 Apr; 5(2):198-203. PubMed ID: 15780831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of fibrinolysis in the development of atherothrombosis: role of adipose tissue.
    Juhan-Vague I; Alessi MC
    Thromb Haemost; 1999 Aug; 82(2):832-6. PubMed ID: 10605790
    [No Abstract]   [Full Text] [Related]  

  • 40. Autonomic dysfunction in rheumatic diseases.
    Straub RH; Baerwald CG; Wahle M; Jänig W
    Rheum Dis Clin North Am; 2005 Feb; 31(1):61-75, viii. PubMed ID: 15639056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.